Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) has experienced a rise in its stock price by 1.71 compared to its previous closing price of 12.59. However, the company has seen a gain of 4.11% in its stock price over the last five trading days. globenewswire.com reported 2025-05-14 that BOSTON and LONDON, May 14, 2025 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for the first quarter ended March 31, 2025.
Is It Worth Investing in Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Right Now?
The 36-month beta value for CNTA is at 1.45. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CNTA is 84.88M, and currently, shorts hold a 6.28% of that float. The average trading volume for CNTA on May 16, 2025 was 922.10K shares.
CNTA’s Market Performance
CNTA stock saw an increase of 4.11% in the past week, with a monthly gain of 8.24% and a quarterly increase of -24.99%. The volatility ratio for the week is 6.38%, and the volatility levels for the last 30 days are 5.99% for Centessa Pharmaceuticals plc ADR (CNTA). The simple moving average for the past 20 days is -1.19% for CNTA’s stock, with a -15.72% simple moving average for the past 200 days.
Analysts’ Opinion of CNTA
Many brokerage firms have already submitted their reports for CNTA stocks, with Chardan Capital Markets repeating the rating for CNTA by listing it as a “Buy.” The predicted price for CNTA in the upcoming period, according to Chardan Capital Markets is $30 based on the research report published on May 08, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see CNTA reach a price target of $38. The rating they have provided for CNTA stocks is “Overweight” according to the report published on March 31st, 2025.
CNTA Trading at -6.94% from the 50-Day Moving Average
After a stumble in the market that brought CNTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.92% of loss for the given period.
Volatility was left at 5.99%, however, over the last 30 days, the volatility rate increased by 6.38%, as shares surge +5.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.43% lower at present.
During the last 5 trading sessions, CNTA rose by +5.69%, which changed the moving average for the period of 200-days by +22.53% in comparison to the 20-day moving average, which settled at $12.97. In addition, Centessa Pharmaceuticals plc ADR saw -23.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNTA starting from HUSSAIN IQBAL J, who sale 311 shares at the price of $14.00 back on May 01 ’25. After this action, HUSSAIN IQBAL J now owns 105,386 shares of Centessa Pharmaceuticals plc ADR, valued at $4,354 using the latest closing price.
HUSSAIN IQBAL J, the General Counsel of Centessa Pharmaceuticals plc ADR, sale 3,609 shares at $14.00 during a trade that took place back on Apr 25 ’25, which means that HUSSAIN IQBAL J is holding 105,386 shares at $50,526 based on the most recent closing price.
Stock Fundamentals for CNTA
The total capital return value is set at -0.39. Equity return is now at value -74.29, with -52.20 for asset returns.
Based on Centessa Pharmaceuticals plc ADR (CNTA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -19.96. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -41.79.
Currently, EBITDA for the company is -221.97 million with net debt to EBITDA at 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.37.
Conclusion
In conclusion, Centessa Pharmaceuticals plc ADR (CNTA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
